Aravax Will Present Peanut Allergy Trial Data in November
The company will unveil Phase 2 results for its PVX108 immunotherapy at upcoming international scientific meetings.
Updated on Oct. 5, 2026 in Allergies
Live Poll
Would you trust a new immunotherapy treatment to manage a severe food allergy for your family?
Aravax is scheduled to present Phase 2 trial results for its peanut allergy immunotherapy, PVX108, throughout November 2026. The randomized, double-blind, placebo-controlled study evaluated the treatment across the United States and Australia.
Why it matters
Aravax aims to provide a differentiated treatment option that retrains the immune system to tolerate peanuts while minimizing the risk of acute allergic reactions. The immunotherapy has already been granted FDA Fast Track designation to support its development.
The study utilized a primary efficacy cohort of children aged 4 to 11 years and an adolescent safety cohort. Participants received PVX108 via intradermal injections over a 12-month period.
The players
Aravax
Aravax is a biotechnology company developing peptide-based immunotherapies to treat peanut allergies.
The details
PVX108 employs proprietary peptides intended to retrain the immune system to tolerate peanut exposure. The treatment is specifically designed to mitigate the risks of acute allergic reactions that can occur during the immunotherapy process.
Timeline
November 12-16, 2026: ACAAI scientific meeting in Phoenix.
November 19-21, 2026: EAACI-FAAM-EUROBAT-ISMA congress in Utrecht.
The Big Picture
The study results represent a significant milestone for clinical trial NCT05621317, which investigates peptide-based approaches to food allergy management. These data will clarify whether intradermal administration can safely induce long-term tolerance in pediatric populations.
The upcoming results could influence future treatment options for children and adolescents suffering from peanut allergies. Families should consult with their healthcare providers regarding the availability of new immunotherapy trials and emerging treatment protocols.
The takeaway
This trial highlights a shift toward using proprietary peptides to induce immune tolerance without triggering adverse allergic reactions. Patients and families are encouraged to monitor clinical trial databases for updates on the commercial availability of these new therapeutic modalities.
What happens next
Aravax will present trial data at the ACAAI scientific meeting in Phoenix from November 12 to 16, 2026, followed by the EAACI-FAAM-EUROBAT-ISMA congress in Utrecht from November 19 to 21, 2026.
Further reading
Learn more about the latest innovations in Allergies.
More information
For more information on the trial and the company's research, visit the Aravax company website.
Live Poll
Would you trust a new immunotherapy treatment to manage a severe food allergy for your family?
